中华耳鼻咽喉头颈外科杂志
中華耳鼻嚥喉頭頸外科雜誌
중화이비인후두경외과잡지
CHINESE JOURNAL OF OTORHINOLARYNGOLOGY HEAD AND NECK SURGERY
2014年
9期
759-764
,共6页
颜康康%林雪君%李双%鲍红红%赵龙宇%刘欣
顏康康%林雪君%李雙%鮑紅紅%趙龍宇%劉訢
안강강%림설군%리쌍%포홍홍%조룡우%류흔
甲状腺肿瘤%癌,乳头状%原癌基因蛋白质B-raf%突变%病理学,临床%Meta分析
甲狀腺腫瘤%癌,乳頭狀%原癌基因蛋白質B-raf%突變%病理學,臨床%Meta分析
갑상선종류%암,유두상%원암기인단백질B-raf%돌변%병이학,림상%Meta분석
Thyroid neoplasms%Carcinoma,papillary%Proto-oncogene protein B-raf%Mutation%Patholog clinical%Meta-analysis
目的 探索甲状腺乳头状癌中BRAFV600E基因突变和病理特征的关联性.方法 检索Medline、PubMed、Web of Science等数据库收集相关文献,应用Meta分析计算比值比(odds ratio,OR)及95％可信区间(confident intervel,CI).结果 共有52篇相关文献纳入研究,12 029例甲状腺乳头状癌患者中BRAFV600E突变率为57.85％.结果显示:在甲状腺乳头状癌中,BRAFV600E基因突变和以下病理特征有关联性:病理分期(OR=1.89,95％ CI为1.58～ 2.27)、淋巴结转移(OR=1.74,95％ CI为1.42 ～2.14)、多灶性(OR=1.25,95％ CI为1.07～ 1.46)、疾病复发(OR=2.26,95％ CI为1.25～4.09).在亚洲人群中BRAFV600E基因突变和以下病理特征有关联性:病理分期(OR=1.56,95％ CI为1.24 ～1.96)、淋巴结转移(OR=1.57,95％CI为1.25～ 1.99).在欧洲人群中BRAFV600E基因突变和以下病理特征有关联性:病理分期(OR=2.63,95％ CI为2.10～3.30)、淋巴结转移(OR=1.97,95％CI为1.19～ 3.25)、多灶性(OR=1.35,95％CI为1.01～ 1.80).结论 病理分期、淋巴结转移、多灶性、疾病复发与BRAFV600E突变有关联性.
目的 探索甲狀腺乳頭狀癌中BRAFV600E基因突變和病理特徵的關聯性.方法 檢索Medline、PubMed、Web of Science等數據庫收集相關文獻,應用Meta分析計算比值比(odds ratio,OR)及95％可信區間(confident intervel,CI).結果 共有52篇相關文獻納入研究,12 029例甲狀腺乳頭狀癌患者中BRAFV600E突變率為57.85％.結果顯示:在甲狀腺乳頭狀癌中,BRAFV600E基因突變和以下病理特徵有關聯性:病理分期(OR=1.89,95％ CI為1.58～ 2.27)、淋巴結轉移(OR=1.74,95％ CI為1.42 ～2.14)、多竈性(OR=1.25,95％ CI為1.07～ 1.46)、疾病複髮(OR=2.26,95％ CI為1.25～4.09).在亞洲人群中BRAFV600E基因突變和以下病理特徵有關聯性:病理分期(OR=1.56,95％ CI為1.24 ～1.96)、淋巴結轉移(OR=1.57,95％CI為1.25～ 1.99).在歐洲人群中BRAFV600E基因突變和以下病理特徵有關聯性:病理分期(OR=2.63,95％ CI為2.10～3.30)、淋巴結轉移(OR=1.97,95％CI為1.19～ 3.25)、多竈性(OR=1.35,95％CI為1.01～ 1.80).結論 病理分期、淋巴結轉移、多竈性、疾病複髮與BRAFV600E突變有關聯性.
목적 탐색갑상선유두상암중BRAFV600E기인돌변화병리특정적관련성.방법 검색Medline、PubMed、Web of Science등수거고수집상관문헌,응용Meta분석계산비치비(odds ratio,OR)급95％가신구간(confident intervel,CI).결과 공유52편상관문헌납입연구,12 029례갑상선유두상암환자중BRAFV600E돌변솔위57.85％.결과현시:재갑상선유두상암중,BRAFV600E기인돌변화이하병리특정유관련성:병리분기(OR=1.89,95％ CI위1.58～ 2.27)、림파결전이(OR=1.74,95％ CI위1.42 ～2.14)、다조성(OR=1.25,95％ CI위1.07～ 1.46)、질병복발(OR=2.26,95％ CI위1.25～4.09).재아주인군중BRAFV600E기인돌변화이하병리특정유관련성:병리분기(OR=1.56,95％ CI위1.24 ～1.96)、림파결전이(OR=1.57,95％CI위1.25～ 1.99).재구주인군중BRAFV600E기인돌변화이하병리특정유관련성:병리분기(OR=2.63,95％ CI위2.10～3.30)、림파결전이(OR=1.97,95％CI위1.19～ 3.25)、다조성(OR=1.35,95％CI위1.01～ 1.80).결론 병리분기、림파결전이、다조성、질병복발여BRAFV600E돌변유관련성.
Objective To evaluate the association between BRAF600E mutation and pathological features in papillary thyroid carcinoma (PTC).Methods The raleted studies were searched through Medline,PubMed,and Web of Science,and meta-analysis was used to calculate the OR and 95％ CI of the study results.Results A total of 52 studies including 12 029 PTC patients was identified.The prevalence of BRAFV600EE mutation in PTC was 57.85％.There was a closed association between the BRAFV600E mutation and pathological features,including advanced TNM stage (OR =1.89,95％ CI 1.58-2.27),lymph node metastasis (OR =1.74,95％ CI 1.42-2.14),multifocality (OR =1.25,95％ CI 1.07-1.46),and recurrence (OR =2.26,95％ CI 1.25-4.09) of PTC.For Asians with PTC,the association between the BRAFV600E mutation and pathological features was indicated for advanced TNM stage(OR =1.56,95％ CI 1.24-1.96) and lymph node metastasis(OR =1.57,95％ CI 1.25-1.99).For Europeans with PTC,the association between the BRAFV600E mutation and pathological features was indicated for advanced TNM stage (OR =2.63,95％ CI 2.10-3.30),lymph node metastasis(OR =1.97,95％ CI 1.19-3.25),and multifocality (OR =1.35,95％ CI 1.01-1.80).Conclusion There were associations between the BRAFV600EE mutation and advanced TNM stage,lymph node metastasis,multifocality,and recurrence of PTC.
